Documentos clave

Ver Toda la documentación

SML0653

Capecitabine

Name: Capecitabine
Brand: SIGMA

≥98% (HPLC), DNA/RNA synthesis inhibitor, powder

Sinónimos:

5′-Deoxy-5-fluoro-N-[(pentyloxy)carbonyl]cytidine, Ro-9-1978

Iniciar sesión para ver los precios por organización y contrato.

Seleccione un Tamaño

Cambiar Vistas

Acerca de este artículo

Fórmula empírica (notación de Hill):

C₁₅H₂₂FN₃O₆

Número CAS:

154361-50-9

Peso molecular:

359.35

UNSPSC Code:

12352200

PubChem Substance ID:

329825576

NACRES:

NA.77

MDL number:

MFCD00930626

Assay:

≥98% (HPLC)

Form:

powder

Quality level:

100

Servicio técnico

¿Necesita ayuda? Nuestro equipo de científicos experimentados está aquí para ayudarle.

Permítanos ayudarle

Propiedades

Nombre del producto

Capecitabine, ≥98% (HPLC)

Quality Level

100

assay

≥98% (HPLC)

form

powder

optical activity

[α]/D +80 to +100°, c = 0.5 in methanol

color

white to beige

solubility

H₂O: 10 mg/mL, clear (warmed)

storage temp.

2-8°C

SMILES string

O[C@H]1[C@@H](O)[C@H](N2C(N=C(NC(OCCCCC)=O)C(F)=C2)=O)O[C@@H]1C

InChI

1S/C15H22FN3O6/c1-3-4-5-6-24-15(23)18-12-9(16)7-19(14(22)17-12)13-11(21)10(20)8(2)25-13/h7-8,10-11,13,20-21H,3-6H2,1-2H3,(H,17,18,22,23)/t8-,10-,11-,13-/m1/s1

InChI key

GAGWJHPBXLXJQN-UORFTKCHSA-N

Gene Information

human ... TYMS(7298)

Descripción

Application

Capecitabine has been used:

in combination with gemcitabine to achieve glutamine deprivation by enhancing the sensitivity of expression in pancreatic ductal adenocarcinoma (PDAC) cells to inhibitors of glutamine metabolism and study its effect on PDAC cell survival
to study the drug metabolic function in a two-organ microfluidic system
as an anti-cancer agent to study its cytotoxic activity alone or in combination with B87 on cancer cells

Biochem/physiol Actions

Capecitabine is an anti-cancer drug, a prodrug of doxifluridine, metabolized to 5-fluorouracil at the tumor site.

Capecitabine is an anti-cancer drug, a prodrug of doxifluridine, metabolized to 5-fluorouracil at the tumor site. The activation of capecitabine follows a pathway with three enzymatic steps and two intermediary metabolites, 5′-Deoxy-5-fluorocytidine (5′-DFCR) and 5′-Deoxy-5-fluorouridine (5′-DFUR), to form 5-fluorouracil.

Still not finding the right product?

Explore all of our products under

pictograms

GHS08

signalword

Danger

hcodes

H341,H350,H360FD

pcodes

P201 - P202 - P280 - P308 + P313 - P405 - P501

Hazard Classifications

Carc. 1B - Muta. 2 - Repr. 1B

Clase de almacenamiento

6.1C - Combustible acute toxic Cat.3 / toxic compounds or compounds which causing chronic effects

wgk

WGK 3

flash_point_f

Not applicable

flash_point_c

Not applicable

Elija entre una de las versiones más recientes:

Certificados de análisis (COA)

Lot/Batch Number

0000521662

0000511613

0000475189

¿No ve la versión correcta?

Si necesita una versión concreta, puede buscar un certificado específico por el número de lote.

Busque por un COA

¿Ya tiene este producto?

Encuentre la documentación para los productos que ha comprado recientemente en la Biblioteca de documentos.

Visite la Librería de documentos

Over 17-month complete clinical brain response with a well-tolerated lapatinib plus capecitabine combination in a very young patient afflicted by HER2-positive metastatic breast cancer.

Valentina Sini et al.

Tumori, 99(6), 273e-277e (2014-02-08)

This report describes a case of ab initio metastatic HER2-positive breast cancer in a very young patient. The onset of breast cancer at such a young age is uncommon and could delay the diagnosis with unquestionable impact on the prognosis.

Phase 2 trial of induction gemcitabine, oxaliplatin, and cetuximab followed by selective capecitabine-based chemoradiation in patients with borderline resectable or unresectable locally advanced pancreatic cancer.

Nestor F Esnaola et al.

International journal of radiation oncology, biology, physics, 88(4), 837-844 (2014-03-13)

To evaluate, in a phase 2 study, the safety and efficacy of induction gemcitabine, oxaliplatin, and cetuximab followed by selective capecitabine-based chemoradiation in patients with borderline resectable or unresectable locally advanced pancreatic cancer (BRPC or LAPC, respectively). Patients received gemcitabine

[Concomitant use of romiplostim and chemotherapy for advanced rectal cancer associated with idiopathic thrombocytopenic purpura].

Moyuru Yamada et al.

Nihon Shokakibyo Gakkai zasshi = The Japanese journal of gastro-enterology, 111(3), 521-528 (2014-03-07)

A woman in her 60s was referred to our department with advanced rectal cancer and multiple unresectable metastases of the liver and peritoneum. She had been diagnosed with idiopathic thrombocytopenic purpura (ITP) in her 20s, with a platelet count maintained

Ver todos los artículos relacionados